Jan. 31, 2020 21:05 UTC CHICAGO--( BUSINESS WIRE )-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on January 29, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 8,500 shares of its common stock to 3 new employees under Xeris’ Induce
January 31, 2020
· 2 min read